The debate over America’s drug-pricing system is built on myths. It’s time to face reality
America’s drug-pricing system is broken.
Any system in which the list price of insulin triples in a decade, leading patients to ration it and sometimes die, is not working. Cancer patients should not worry that their disease will bankrupt them. The U.S. insurance system, which has instead gone decades without making tough decisions about how to pay for medicines, should not be passing on so many costs to patients.
